Timetable Update
19 déc. 2019 02h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Timetable update for the proposed Subscription and Placing Oxford, UK, and Cambridge, MA, US, 19 December 2019 - Summit...
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
17 déc. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended...
Notice of Q3 Results
16 déc. 2019 09h15 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2019 on 17 December 2019 Oxford, UK, and...
Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
06 déc. 2019 07h24 HE
|
Summit Therapeutics plc
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN...
Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
06 déc. 2019 07h00 HE
|
Summit Therapeutics plc
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR...
Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
06 nov. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress Oxford, UK, and Cambridge, MA, US, 6 November...
Summit Therapeutics Recognises C. difficile Awareness Month
04 nov. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Recognises C. difficile Awareness Month Company to Highlight Potential of Phase 3 Precision Antibiotic Ridinilazole...
Summit Therapeutics to Present at the 2019 BIO Investor Forum
16 oct. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2019 BIO Investor Forum Oxford, UK, and Cambridge, MA, US, 16 October 2019 – Summit...
Directorate change
11 oct. 2019 07h01 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Director Change Oxford, UK, and Cambridge, MA, US, 11 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism...
Half-year report
11 oct. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended 31 July 2019 ...